Magid Abou-Gharbia - Publications

Affiliations: 
Pharmaceutical Sciences Temple University, Philadelphia, PA, United States 
Area:
Pharmacology, Inorganic Chemistry, Pharmacy
Website:
https://moulder.temple.edu/about-us/director

94 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Childers WE, Abou-Gharbia MA. "I'll Be Back": The Resurrection of Dezocine. Acs Medicinal Chemistry Letters. 12: 961-968. PMID 34141081 DOI: 10.1021/acsmedchemlett.1c00233  0.01
2021 El-Awady R, Saleh E, Hamoudi R, Ramadan WS, Mazitschek R, Nael MA, Elokely KM, Abou-Gharbia M, Childers WE, Srinivasulu V, Aloum L, Menon V, Al-Tel TH. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents. Bioorganic & Medicinal Chemistry. 42: 116251. PMID 34116381 DOI: 10.1016/j.bmc.2021.116251  0.01
2021 Knackstedt LA, Wu L, Rothstein JD, Vidensky S, Gordon J, Ramanjulu M, Dunman P, Blass B, Childers W, Abou-Gharbia M. MC-100093, a novel β-lactam GLT-1 enhancer devoid of antimicrobial properties attenuates cocaine relapse in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 33986035 DOI: 10.1124/jpet.121.000532  0.01
2021 Manandhar A, Blass BE, Colussi DJ, Almi I, Abou-Gharbia M, Klein ML, Elokely KM. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: Modeling and Screening. Journal of Chemical Information and Modeling. PMID 33538596 DOI: 10.1021/acs.jcim.0c01457  0.01
2020 Al-Ashmawy AAK, Elokely KM, Perez-Leal O, Rico M, Gordon J, Mateo G, Omar AM, Abou-Gharbia M, Childers WE. Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3Kalpha/mTOR Inhibitors Targeting Breast Cancer. Acs Medicinal Chemistry Letters. 11: 2156-2164. PMID 33214824 DOI: 10.1021/acsmedchemlett.0c00289  0.01
2020 Childers WE, Elokely KM, Abou-Gharbia M. The Resurrection of Phenotypic Drug Discovery. Acs Medicinal Chemistry Letters. 11: 1820-1828. PMID 33062159 DOI: 10.1021/Acsmedchemlett.0C00006  0.01
2019 Childers W, Fan R, Martinez R, Colussi DJ, Melenski E, Liu Y, Gordon J, Abou-Gharbia M, Jacobson MA. Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells. Bioorganic & Medicinal Chemistry Letters. 126806. PMID 31757667 DOI: 10.1016/J.Bmcl.2019.126806  0.01
2018 Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, ... ... Abou-Gharbia M, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 175: 1244-1258.e26. PMID 30454645 DOI: 10.1016/J.Cell.2018.09.051  0.01
2018 Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Reddy Nimmareddy R, Paliwal S, Rajasekhar J, Shivakumar S, et al. Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17). Bioorganic & Medicinal Chemistry Letters. PMID 29803730 DOI: 10.1016/J.Bmcl.2018.05.040  0.01
2018 Lounsbury N, Eidem T, Colquhoun J, Mateo G, Abou-Gharbia M, Dunman PM, Childers WE. Novel inhibitors of Staphylococcus aureus RnpA that synergize with mupirocin. Bioorganic & Medicinal Chemistry Letters. PMID 29463447 DOI: 10.1016/J.Bmcl.2018.01.022  0.01
2018 Zhang H, Pandey S, Travers M, Khowsathit J, Morton G, Sum H, Barrero CA, Merali C, Okamoto Y, Sato T, Garriga J, Bhanu NV, Simithy J, Patel B, Madzo J, ... ... Abou-Gharbia M, et al. Abstract 2952: Targeting CDK9 reactivates epigenetically silenced genes in cancer Cancer Research. 78: 2952-2952. DOI: 10.1158/1538-7445.Am2018-2952  0.01
2017 Bryant KG, Chae YC, Martinez RL, Gordon JC, Elokely KM, Kossenkov AV, Grant S, Childers WE, Abou-Gharbia M, Altieri DC. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget. 8: 112184-112198. PMID 29348817 DOI: 10.18632/Oncotarget.23097  0.01
2017 Al-Ashmawy AAK, Ragab FA, Elokely KM, Anwar MM, Perez-Leal O, Rico MC, Gordon J, Bichenkov E, Mateo G, Kassem EMM, Hegazy GH, Abou-Gharbia M, Childers W. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 28571824 DOI: 10.1016/J.Bmcl.2017.05.044  0.01
2017 Coric P, Saribas AS, Abou-Gharbia M, Childers W, Condra J, White MK, Safak M, Bouaziz S. Nuclear Magnetic Resonance Structure of the Human Polyoma JC Virus Agnoprotein. Journal of Cellular Biochemistry. PMID 28295503 DOI: 10.2210/Pdb5Nhq/Pdb  0.01
2017 Abou-Gharbia M, Blass B, Childers W, Ramanjulu M, Melenski E. Glutamate transporter-1 (GLT-1): a potential therapeutic target for the treatment of central nervous system diseases and disorders Drugs of the Future. 42: 489. DOI: 10.1358/Dof.2017.042.08.2658258  0.01
2017 Zhang H, Raynal NJ-, Sato T, Okamoto Y, Garriga J, Garcia B, Morton G, Childers W, Jacobson MA, Baylin SB, Graña X, Abou-Gharbia M, Issa JJ. Abstract 5064: Identifying novel potential epigenetic anti-cancer drugs from natural compounds using a phenotypic-based screening Cancer Research. 77: 5064-5064. DOI: 10.1158/1538-7445.Am2017-5064  0.01
2016 Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Nimmareddy RR, Paliwal S, Rajasekhar J, Shivakumar S, et al. Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome. Bioorganic & Medicinal Chemistry Letters. PMID 27789139 DOI: 10.1016/J.Bmcl.2016.10.016  0.01
2016 Di Meco A, Li JG, Blass BE, Abou-Gharbia M, Lauretti E, Praticò D. 12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice. Biological Psychiatry. PMID 27499089 DOI: 10.1016/J.Biopsych.2016.05.023  0.01
2016 Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports. PMID 27452461 DOI: 10.1016/J.Celrep.2016.06.091  0.01
2016 Saribas AS, Coric P, Hamazaspyan A, Davis W, Axman R, White MK, Abou-Gharbia M, Childers W, Condra JH, Bouaziz S, Safak M. Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses Journal of Cellular Physiology. 231: 2115-2127. PMID 26831433 DOI: 10.1002/Jcp.25329  1
2016 Zhang H, Raynal NJ-, Sato T, Okamoto Y, Garcia B, Morton G, Childers W, Jacobson MA, Baylin SB, Abou-Gharbia M, Issa JJ. Abstract B50: A phenotypic screen to identify novel potential epigenetic anticancer drugs from natural compounds Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B50  0.01
2016 Zhang H, Raynal NJ-, Sato T, Okamoto Y, Garriga J, Morton G, Childers W, Jacobson MA, Baylin SB, Graña X, Abou-Gharbia M, Issa JJ. Abstract 4701: A phenotypic cell-based screen to identify novel potential epigenetic anti-cancer drugs from natural compounds Cancer Research. 76: 4701-4701. DOI: 10.1158/1538-7445.Am2016-4701  0.01
2015 Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Research. PMID 26719529 DOI: 10.1158/0008-5472.Can-14-2391  1
2015 Lounsbury N, Mateo G, Jones B, Papaiahgari S, Thimmulappa RK, Teijaro C, Gordon J, Korzekwa K, Ye M, Allaway G, Abou-Gharbia M, Biswal S, Childers W. Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. Bioorganic & Medicinal Chemistry. 23: 5352-9. PMID 26278028 DOI: 10.1016/J.Bmc.2015.07.056  0.01
2015 Eidem TM, Lounsbury N, Emery JF, Bulger J, Smith A, Abou-Gharbia M, Childers W, Dunman PM. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrobial Agents and Chemotherapy. 59: 2016-28. PMID 25605356 DOI: 10.1128/Aac.04352-14  1
2015 Chu J, Li JG, Giannopoulos PF, Blass BE, Childers W, Abou-Gharbia M, Praticò D. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice. Molecular Psychiatry. PMID 25560760 DOI: 10.1038/Mp.2014.170  0.01
2015 Zhang H, Raynal N, Sato T, Okamoto Y, Henry R, Andrews AJ, Morton G, Childers W, Jacobson MA, Abou-Gharbia M, Issa JJ. Abstract 3519: A phenotypic screen to discover novel epigenetic anticancer drugs from natural compounds Cancer Research. 75: 3519-3519. DOI: 10.1158/1538-7445.Am2015-3519  0.01
2014 Coric P, Saribas AS, Abou-Gharbia M, Childers W, White MK, Bouaziz S, Safak M. Nuclear magnetic resonance structure revealed that the human polyomavirus JC virus agnoprotein contains an α-helix encompassing the Leu/Ile/Phe-rich domain. Journal of Virology. 88: 6556-75. PMID 24672035 DOI: 10.1128/Jvi.00146-14  0.01
2014 Butts A, Koselny K, Chabrier-Roselló Y, Semighini CP, Brown JC, Wang X, Annadurai S, DiDone L, Tabroff J, Childers WE, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. Mbio. 5: e00765-13. PMID 24520056 DOI: 10.1128/Mbio.00765-13  1
2014 Abou-Gharbia M, Childers WE. Discovery of innovative therapeutics: Today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation Journal of Medicinal Chemistry. 57: 5525-5553. PMID 24428137 DOI: 10.1021/Jm401564R  1
2014 Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, Sharom FJ, Chaudhury S, Abdulhameed MD, Tawa G, Wallqvist A, Martinez R, Childers W, Abou-Gharbia M, Krynetskiy E, et al. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorganic & Medicinal Chemistry. 22: 1148-55. PMID 24405813 DOI: 10.1016/J.Bmc.2013.12.022  1
2014 Perez-Leal O, Abou-Gharbia M, Gordon J, Childers WE, Merali S. A novel assay platform for the detection of translation modulators of spermidine/spermine acetyltransferase. Current Pharmaceutical Design. 20: 245-52. PMID 23701549 DOI: 10.2174/13816128113199990035  0.01
2014 Abou-Gharbia M. Discovery of innovative small-molecule therapeutics Hamdan Medical Journal. 7. DOI: 10.7707/Hmj.393  0.01
2014 Abou-Gharbia M. Discovery of first-in-class therapeutics – venlafaxine (Effexor®), desvenlafaxine (Pristiq®), temsirolimus (Toresil®), ILS-920 and gemtuzumab ozogamicin (Mylotarg®) Hamdan Medical Journal. 7: 317. DOI: 10.7707/Hmj.346  0.01
2014 Coric P, Saribas SA, Abou-Gharbia M, Childers W, White M, Bouaziz S, Safak M. The structure of the dimerization domain of the human polyoma, JC virus agnoprotein is an amphipathic alpha-helix Journal of Virology. DOI: 10.2210/Pdb2Mj2/Pdb  0.01
2014 Raynal NJ, Lee JT, Wang Y, Garriga J, Malouf G, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews A, Jelinek J, et al. Abstract 380: Discovery of new epigenetic drugs among FDA-approved drug libraries Cancer Research. 74: 380-380. DOI: 10.1158/1538-7445.Am2014-380  0.01
2014 Coric P, Saribas AS, Abou-Gharbia M, Childers W, White MK, Bouaziz S, Safak M. Correction for Coric et al., Nuclear Magnetic Resonance Structure Revealed that the Human Polyomavirus JC Virus Agnoprotein Contains an α-Helix Encompassing the Leu/Ile/Phe-Rich Domain Journal of Virology. 88: 11000-11000. DOI: 10.1128/Jvi.01718-14  0.01
2013 Sami Saribas A, Abou-Gharbia M, Childers W, Sariyer IK, White MK, Safak M. Essential roles of Leu/Ile/Phe-rich domain of JC virus agnoprotein in dimer/oligomer formation, protein stability and splicing of viral transcripts. Virology. 443: 161-76. PMID 23747198 DOI: 10.1016/J.Virol.2013.05.003  1
2013 Abou-Gharbia M, Childers WE. Discovery of innovative therapeutics: Today's realities and tomorrow's vision. 1. Criticisms faced by the pharmaceutical industry Journal of Medicinal Chemistry. 56: 5659-5672. PMID 23557017 DOI: 10.1021/Jm400330J  1
2013 Moni L, Marra A, Skotnicki JS, Koehn FE, Abou-Gharbia M, Dondoni A. Synthesis of rapamycin glycoconjugates via a CuAAC-based approach Tetrahedron Letters. 54: 6999-7003. DOI: 10.1016/J.Tetlet.2013.10.026  1
2012 Annadurai S, Martinez R, Canney DJ, Eidem T, Dunman PM, Abou-Gharbia M. Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA. Bioorganic & Medicinal Chemistry Letters. 22: 7719-25. PMID 23116888 DOI: 10.1016/J.Bmcl.2012.09.095  1
2012 Abou-Gharbia M, Childers W. Targeting neurodegenerative diseases: Drug discovery in a challenging arena Pure and Applied Chemistry. 84: 1543-1556. DOI: 10.1351/Pac-Con-11-11-09  1
2011 Ghidu VP, Ilies MA, Cullen T, Pollet R, Abou-Gharbia M. A new and efficient synthetic route for the anxiolytic agent CL285032. Bioorganic & Medicinal Chemistry Letters. 21: 259-61. PMID 21095124 DOI: 10.1016/J.Bmcl.2010.11.017  1
2010 Rawls SM, Karaca F, Madhani I, Bhojani V, Martinez RL, Abou-Gharbia M, Raffa RB. β-lactamase inhibitors display anti-seizure properties in an invertebrate assay. Neuroscience. 169: 1800-4. PMID 20600649 DOI: 10.1016/J.Neuroscience.2010.06.041  1
2010 Childers WE, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, et al. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists. Journal of Medicinal Chemistry. 53: 4066-84. PMID 20443629 DOI: 10.1021/Jm1000908  1
2009 Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, ... ... Abou-Gharbia M, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 331: 598-608. PMID 19671883 DOI: 10.1124/Jpet.109.152975  1
2009 Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Liu W, McCampbell AS, Dave B, Broaddus RR, Brown EL, Kao W, Skotnicki JS, ... Abou-Gharbia M, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Research. 69: 6171-8. PMID 19622772 DOI: 10.1158/0008-5472.Can-08-4471  1
2009 Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, Magolda R, Sze JY, Brandt MR, Cummons TA, Kowal D, Pangalos MN, Zupan B, Hoffmann M, May M, et al. Prodrugs of perzinfotel with improved oral bioavailability. Journal of Medicinal Chemistry. 52: 771-8. PMID 19146418 DOI: 10.1021/jm8011799  1
2009 Abou-Gharbia M. Discovery of innovative small molecule therapeutics. Journal of Medicinal Chemistry. 52: 2-9. PMID 19072120 DOI: 10.1021/Jm8012823  0.01
2008 Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, et al. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry. 51: 7348-51. PMID 19012391 DOI: 10.1021/Jm801252W  1
2008 Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, ... ... Abou-Gharbia M, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proceedings of the National Academy of Sciences of the United States of America. 105: 8754-9. PMID 18559859 DOI: 10.1073/pnas.0710823105  1
2008 Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, von Schack D, McDonald L, Zaleska MM, Wood A, ... ... Abou-Gharbia M, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proceedings of the National Academy of Sciences of the United States of America. 105: 33-8. PMID 18162540 DOI: 10.1073/Pnas.0710424105  1
2008 Ruan BH, Pong K, Jow F, Bowlby M, Crozier R, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, Schack Dv, McDonald L, Zaleska M, Wood A, ... ... Abou-Gharbia M, et al. Binding of novel rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities The Faseb Journal. 22: 619-619. DOI: 10.1096/Fasebj.22.2_Supplement.619  0.01
2008 Malamas M, Erdei J, Gunawan I, Robichaud A, Turner J, Hu Y, Wagner E, Aschmies S, Comery T, Fan K, Chopra R, Magolda R, Pangalos M, Reinhart P, Riddell D, ... ... Abou-Gharbia M, et al. P2-481: Small molecule BACE-1 inhibitors are potent, selective and orally active Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1559  0.01
2006 Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH. Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor Journal of Pharmacology and Experimental Therapeutics. 318: 657-665. PMID 16675639 DOI: 10.1124/Jpet.106.103382  0.01
2005 Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, ... ... Abou-Gharbia M, et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. The Journal of Pharmacology and Experimental Therapeutics. 314: 1274-89. PMID 15951399 DOI: 10.1124/Jpet.105.086363  1
2005 Childers WE, Abou-Gharbia MA, Kelly MG, Andree TH, Harrison BL, Ho DM, Hornby G, Huryn DM, Potestio L, Rosenzweig-Lipson SJ, Schmid J, Smith DL, Sukoff SJ, Zhang G, Schechter LE. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan. Journal of Medicinal Chemistry. 48: 3467-70. PMID 15887953 DOI: 10.1021/Jm049493Z  1
2004 Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization Journal of Medicinal Chemistry. 47: 3491-3494. PMID 15214776 DOI: 10.1021/Jm049766Q  1
2004 Elokdah H, Sulkowski TS, Abou-Gharbia M, Butera JA, Chai SY, McFarlane GR, McKean ML, Babiak JL, Adelman SJ, Quinet EM. Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties. Journal of Medicinal Chemistry. 47: 681-95. PMID 14736248 DOI: 10.1021/Jm030219Z  1
2004 Pangalos MN, Smith DL, Rosenzweig-Lipson S, Sukoff S, Dawson L, Marquis K, Jones D, Piesla M, Andree T, Harder J, Womack M, Buccafusco J, Terry AV, Hoebel B, Rada P, ... ... Abou-Gharbia M, et al. P1-319 SRA-333: a novel 5-HT1A receptor antagonist with procognitive properties in nonhuman primates Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80632-8  0.04
1999 Sabb AL, Husbands GM, Tokolics J, Stein RP, Tasse RP, Boast CA, Moyer JA, Abou-Gharbia M. Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling. Bioorganic & Medicinal Chemistry Letters. 9: 1895-900. PMID 10450949 DOI: 10.1016/S0960-894X(99)00313-3  1
1998 Mewshaw RE, Husbands M, Gildersleeve ES, Webb MB, Shi X, Mazandarani H, Cockett MI, Ochalski R, Brennan JA, Abou-Gharbia M, Marquis K, McGaughey GB, Coupet J, Andree TH. New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates Bioorganic and Medicinal Chemistry Letters. 8: 295-300. PMID 9871673 DOI: 10.1016/S0960-894X(98)00014-6  1
1998 Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, Miller TL, Tasse RP, Zaleska MM, Moyer JA. Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere. Journal of Medicinal Chemistry. 41: 236-46. PMID 9457246 DOI: 10.1021/Jm970504G  1
1998 Mewshaw RE, Marquis KL, Shi X, McGaughey G, Stack G, Webb MB, Abou-Gharbia M, Wasik T, Scerni R, Spangler T, Brennan JA, Mazandarani H, Coupet J, Andree TH. New generation dopaminergic agents 4. Exploiting the 2-methyl chroman scaffold. Synthesis and evaluation of two novel series of 2-(aminomethyl)- 3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and indol-8-one derivatives Tetrahedron. 54: 7081-7108. DOI: 10.1016/S0040-4020(98)00349-4  1
1997 Mewshaw RE, Kavanagh J, Stack G, Marquis KL, Shi X, Kagan MZ, Webb MB, Katz AH, Park A, Kang YH, Abou-Gharbia M, Scerni R, Wasik T, Cortes-Burgos L, Spangler T, et al. New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans Journal of Medicinal Chemistry. 40: 4235-4256. PMID 9435894 DOI: 10.1021/Jm9703653  1
1997 Sabb AL, Stein RP, Vogel RL, Tasse R, Amburn S, Fairman DK, Kowal D, Malhotra D, Boast CA, Bartolomeo A, Morris H, Sailer T, Moyer JA, Abou-Gharbia M, Ho DM. WAY-131256 is an orally active, efficacious, and in vivo functionally selective M1 agonist Drug Development Research. 40: 185-192. DOI: 10.1002/(Sici)1098-2299(199702)40:2<185::Aid-Ddr8>3.0.Co;2-H  1
1995 Abou-Gharbia M, Moyer JA, Nielsen ST, Webb M, Patel U. New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists. Journal of Medicinal Chemistry. 38: 4026-32. PMID 7562938 DOI: 10.1021/Jm00020A018  1
1993 Abou-Gharbia M, Ablordeppey SY, Glennon RA. Chapter 1. Sigma Receptors and their Ligands: The Sigma Enigma Annual Reports in Medicinal Chemistry. 28: 1-10. DOI: 10.1016/S0065-7743(08)60871-4  0.01
1991 Abou-Gharbia M, Marquis K, Andree T. Wy-47,791 Drugs of the Future. 16: 1008. DOI: 10.1358/Dof.1991.016.11.154510  0.01
1990 Abou-Gharbia M, Moyer JA. Wy-50,324 Drugs of the Future. 15: 1093. DOI: 10.1358/Dof.1990.015.11.147140  0.01
1990 Abou-Gharbia M. Wy-49,051 Drugs of the Future. 15: 137. DOI: 10.1358/Dof.1990.015.02.114545  0.01
1990 Abou-Gharbia M, Moyer JA. Chapter 1. Novel Antipsychotic Agents Annual Reports in Medicinal Chemistry. 25: 1-10. DOI: 10.1016/S0065-7743(08)61577-8  0.01
1989 Abou-Gharbia M, Moyer JA, Patel U, Webb M, Schiehser G, Andree T, Haskins JT. Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents. Journal of Medicinal Chemistry. 32: 1024-33. PMID 2565399 DOI: 10.1021/Jm00125A016  1
1988 Abou-Gharbia M, Patel UR, Webb MB, Moyer JA, Andree TH, Muth EA. Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies. Journal of Medicinal Chemistry. 31: 1382-92. PMID 2898533 DOI: 10.1021/Jm00402A023  1
1988 Abou-Gharbia M, Patel U, Tokolics J, Freed M. Synthesis and anti-arrhythmic activity of cycloalkaneindoles European Journal of Medicinal Chemistry. 23: 373-377. DOI: 10.1016/0223-5234(88)90211-5  0.01
1987 Abou-Gharbia M, Patel UR, Webb MB, Moyer JA, Andree TH, Muth EA. Antipsychotic activity of substituted gamma-carbolines. Journal of Medicinal Chemistry. 30: 1818-23. PMID 2888898 DOI: 10.1021/Jm00393A023  1
1987 Abou-Gharbia M, Patel UR, Moyer JA, Muth EA. Psychotropic agents: synthesis and antipsychotic activity of substituted beta-carbolines. Journal of Medicinal Chemistry. 30: 1100-5. PMID 2884314 DOI: 10.1021/Jm00389A022  1
1986 Abou-Gharbia M. Synthesis of Novel Hexahydroquinolines and Hexahydroacridines Heterocycles. 24: 1347-1353. DOI: 10.1002/Chin.198641240  0.01
1985 Abou-Gharbia M, Hoffman BR. A New Synthesis Of 2-Bromo-1-(9-Phenanthryl)Ethane Organic Preparations and Procedures International. 16: 195-198. DOI: 10.1080/00304948509355500  0.01
1985 Abou-Gharbia M, Ketcha DM, Zacharias DE, Swern D. Reactions of ketenes with sulfilimines. Synthetic routes to oxazolinones and indolinones Journal of Organic Chemistry. 50: 2224-2228. DOI: 10.1021/Jo00213A005  0.04
1985 Abou-Gharbia M, Ketcha DM, Zacharias DE, Swern D. Reactions Of Ketenes With Sulfilimines. Synthetic Routes To Oxazolinones And Indolinones Cheminform. 16. DOI: 10.1002/Chin.198543235  0.01
1985 Abou-Gharbia M, Freed ME, Mccaully RJ, Silver PJ, Wendt RL. Tetrahydropyrrolo(1,2-A)Quinoxalines And Tetrahydropyrrolo(1,2-A)Pyrido(3,2-A)Pyrazines: Vascular Smooth Muscle Relaxants And Antihypertensive Agents Cheminform. 16. DOI: 10.1002/Chin.198523227  0.04
1985 Abou-Gharbia M, Cheeseman EN, Pashko L, Schwartz A, Swern D. EPIANDROSTERONE- AND DEHYDROEPIANDROSTERONE-3β-ALKANESULFONATES AS INHIBITORS OF MOUSE GLUCOSE-6-PHOSPHATE DEHYDROGENASE ACTIVITY Cheminform. 16. DOI: 10.1002/Chin.198521326  0.01
1984 Abou-Gharbia M, Cheeseman EN, Pashko L, Schwartz A, Swern D. Epiandrosterone- and Dehydroepiandrosterone-3β-alkanesulfonates as Inhibitors of Mouse Glucose-6-phosphate Dehydrogenase Activity Journal of Pharmaceutical Sciences. 73: 1643-1645. PMID 6520773 DOI: 10.1002/Jps.2600731140  0.01
1984 Abou-Gharbia M, Freed ME, McCaully RJ, Silver PJ, Wendt RL. Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents. Journal of Medicinal Chemistry. 27: 1743-6. PMID 6502606 DOI: 10.1021/Jm00378A039  1
1983 Ketcha DM, Abou-Gharbia M, Smith FX, Swern D. Reaction of N-acylsulfilimines with diphenyl ketene. A new synthesis of 2-oxazolin-4-ones Tetrahedron Letters. 24: 2811-2814. DOI: 10.1016/S0040-4039(00)88030-2  0.08
1982 Abou-Gharbia M, Pashko L, Schwartz A, Swern D. SYNTHESIS OF DEHYDROEPIANDROSTERONE SULFATIDE AND 16α-HALOGENATED STEROIDS Cheminform. 13. DOI: 10.1002/Chin.198213319  0.01
1981 Abou-Gharbia M, Pashko L, Schwartz A, Swern D. Synthesis of dehydroepiandrosterone sulfatide and 16α‐Halogenated steroids Journal of Pharmaceutical Sciences. 70: 1154-1157. PMID 6457907 DOI: 10.1002/Jps.2600701017  0.01
1981 Pashko LL, Schwartz AG, Abou-gharbia M, Swern D. Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids Carcinogenesis. 2: 717-721. PMID 6456847 DOI: 10.1093/Carcin/2.8.717  1
1981 Henderson E, Schwartz A, Pashko L, Abou-Gharbia M, Swern D. Dehydroepiandrosterone and 16α-bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes Carcinogenesis. 2: 683-686. PMID 6268330 DOI: 10.1093/Carcin/2.7.683  0.01
1980 Abou-Gharbia M, Joullie M. Additions and Corrections - Cyclo-additions of Ketenes with N-Fluorenylidenealklamine and -arylamine Oxides. Synthesis of Spirooxazolidinones and Spiroisoxazolidinones The Journal of Organic Chemistry. 45: 5432-5432. DOI: 10.1021/Jo01314A605  0.04
1978 ABOU-GHARBIA M, JOULLIE MM. ChemInform Abstract: SYNTHESIS AND HYDROLYSIS OF FLUORENE-9-SPIRO-2′-(N-ARYL-3′,3′-DICHLOROAZIRIDINES) Chemischer Informationsdienst. 9. DOI: 10.1002/Chin.197816166  0.44
1977 Abou-Gharbia M, Joullié MM. Synthesis and hydrolysis of fluorene-9-spiro-2'-(N-aryl-3' ,3'-dichloroaziridines) Journal of Pharmaceutical Sciences. 66: 1653-5. PMID 915756 DOI: 10.1002/Jps.2600661146  0.01
1977 ABOU-GHARBIA M, JOULLIÉ MM. A New Synthesis of Nitrones Synthesis. 1977: 318-320. DOI: 10.1055/S-1977-24378  0.6
Show low-probability matches.